|
|
Other links at Articles > Pharmacists |
| 4. |
Triple-Drug Combo Improves Breast Cancer Outcomes With Low Cardiotoxicity
|
|
|
The addition of trastuzumab (Herceptin) to epirubicin and cyclophosphamide as first-line therapy improves survival with low dose-limiting cardiotoxicity in women with human epidermal growth factor receptor (HER)-2 positive metastatic breast cancer, new research shows. Reuters Health Information
|
|
|